SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMCNet:  Genkyotex Appoints Daniel Elger as Chief Financial and Corporate Development Officer

[June 11, 2014]

Genkyotex Appoints Daniel Elger as Chief Financial and Corporate Development Officer

GENEVA & ARCHAMPS, France --(Business Wire)--

Genkyotex, the leading developer of selective NOX enzyme inhibitors, announced today the appointment of Dr. Daniel Elger as Chief Financial and Corporate Development Officer. He joins Genkyotex with more than 15 years biotech and pharmaceutical industry experience.

"Daniel's extensive strategic expertise, including experience in fundraising and the public markets, is a great asset to the Genkyotex team," stated Dr. Ursula Ney, Chief Executive Officer. "As Genkyotex grows and we advance our clinical pipeline, Daniel will play a key role in further developing our corporate strategy to leverage our world leading position in developing this new drug class of NOX inhibitors."

Dr. Elger was most recently Chief Financial Officer and a Board Director of e-Therapeutics plc, a London Stock Exchange (LSE) AIM-listed drug discovery and development company, where he played a central role in a substantial fundraising. Prior to that role, he was Vice President, Marketing and Communications, at LSE-listed oncology comany Antisoma plc, where he served on the Senior Management Team and had significant roles in corporate strategy, fundraisings and the acquisition of two US biotech companies, as well as directing the company's investor relations and communications programmes. Earlier in his career, Dr. Elger worked in marketing and communications agencies serving major pharma companies. He holds a BA in Physiological Sciences (Medicine) and a PhD in cancer cell biology, both from Oxford University.


About Genkyotex

Genkyotex is developing first in class, small molecule therapeutics that specifically and selectively inhibit the NOX family of enzymes. Using a unique screening platform, Genkyotex has identified novel NOX inhibitors with the potential to treat disease areas with a high clinical need and large market potential. The company's lead product, GKT137831, is now in a Phase 2 clinical study in patients with diabetic nephropathy and has shown promise in several other disease models, including atherosclerosis, lung and liver fibrosis, osteoporosis, and in models of angiogenesis. Genkyotex was founded in 2006 by scientists from Switzerland, the USA and Japan, with backing from Geneva incubator Eclosion. Since 2011, expansion of the investor base, led by Edmond de Rothschild Investment Partners, with Vesalius BioCapital and MP Healthcare Venture Management, has provided significant investment to Genkyotex. Further information can be found at: www.genkyotex.com.


[ Back To Technology News's Homepage ]

OTHER NEWS PROVIDERS







Technology Marketing Corporation

800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2014 Technology Marketing Corporation. All rights reserved | Privacy Policy